{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:43Z","timestamp":1789958803280,"version":"4.0.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant translocations may involve one or more chromosomes in addition to 9 and 22, and can be generated by 2 different mechanisms, 1-step and 2-step rearrangements, as revealed by fluorescence in situ hybridization. The prognostic significance of the occurrence of variant translocations has been discussed in previous studies. The European LeukemiaNet recommendations do not provide a \u201cwarning\u201d for patients with variant translocations, but there is limited information about their outcome after therapy with tyrosine kinase inhibitors. To identify the role of variant translocations in early chronic phase (CP) CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective imatinib trials of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML. Variant translocations occurred in 30 patients (5%). Our data show that the presence of variant translocations has no impact on the cytogenetic and molecular response or on outcome, regardless of the involvement of different mechanisms, the number of involved chromosomes, or the presence of deletions. Therefore, we suggest that patients with variant translocations do not constitute a \u201cwarning\u201d category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926.<\/jats:p>","DOI":"10.1182\/blood-2011-01-328294","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T00:41:12Z","timestamp":1301445672000},"page":"6793-6800","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":92,"title":["Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis"],"prefix":"10.1182","volume":"117","author":[{"given":"Giulia","family":"Marzocchi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Luatti","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baldazzi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Stacchini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina","family":"Amabile","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[{"name":"Hematology, University of Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sessarego","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova, Genova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Giussani","sequence":"additional","affiliation":[{"name":"Cytogenetics Unit, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Valori","sequence":"additional","affiliation":[{"name":"Cytogenetics Unit, Treviso, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Discepoli","sequence":"additional","affiliation":[{"name":"Centre of Medical Genetic and Prenatal Diagnosis, Ancona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Montaldi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vicenza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biotechnological Research, A.O.U. \u201cCervello,\u201d Palermo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonaldi","sequence":"additional","affiliation":[{"name":"Molecolar Oncology and Cytodiagnostic Unit, University of Padova, Padova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giudici","sequence":"additional","affiliation":[{"name":"Research Center \u201cTettamanti,\u201d Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cianciulli","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department \u201cRegina Elena Institute,\u201d Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giacobbi","sequence":"additional","affiliation":[{"name":"Hematology University of Modena, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Biotechnology, \u201cFederico II\u201d University, Napoli, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Testoni","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5405","key":"2019111713152121500_B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2019111713152121500_B2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminhematol.2006.12.001","article-title":"Introduction: chronic myelogenous leukemia (CML).","volume":"44","author":"Jabbour","year":"2007","journal-title":"Semin Hematol"},{"issue":"8","key":"2019111713152121500_B3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia.","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111713152121500_B4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.10.006","article-title":"On the genesis and prognosis of variant translocations in chronic myeloid leukemia.","volume":"173","author":"Gorusu","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2019111713152121500_B5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00193575","article-title":"Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia.","volume":"85","author":"Huret","year":"1990","journal-title":"Hum Genet"},{"issue":"2","key":"2019111713152121500_B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2008.01.005","article-title":"Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.","volume":"182","author":"Richebourg","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2019111713152121500_B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cancergencyto.2009.05.010","article-title":"Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.","volume":"194","author":"Bennour","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2019111713152121500_B8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.","volume":"125","author":"El-Zimaity","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111713152121500_B9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111713152121500_B10","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111713152121500_B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cancergencyto.2008.01.007","article-title":"Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.","volume":"182","author":"De Melo","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"11","key":"2019111713152121500_B12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111713152121500_B13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia.","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2019111713152121500_B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111713152121500_B15","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"2019111713152121500_B16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"key":"2019111713152121500_B17","volume-title":"ISCN 2009: International System of Human Cytogenetic Nomenclature","author":"Shaffer","year":"2009"},{"issue":"24","key":"2019111713152121500_B18","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111713152121500_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexmp.2006.03.004","article-title":"Conventional cytogenetics and FISH in the detection of BCR\/ABL fusion in chronic myeloid leukemia (CML).","volume":"81","author":"Mark","year":"2006","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"2019111713152121500_B20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cancergencyto.2006.09.025","article-title":"\u201cHome-brew\u201d FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.","volume":"174","author":"Albano","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111713152121500_B21","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"2019111713152121500_B22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"2019111713152121500_B23","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2013a Europe Against Cancer program.","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111713152121500_B24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111713152121500_B25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2019111713152121500_B26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111713152121500_B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"issue":"9","key":"2019111713152121500_B28","first-page":"ECR37","article-title":"Complex variant Philadelphia translocation involving the short arm of chromosome 9 in a case of chronic myeloid leukemia.","volume":"89","author":"Cianciulli","year":"2004","journal-title":"Haematologica"},{"issue":"35","key":"2019111713152121500_B29","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111713152121500_B30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0165-4608(84)90034-7","article-title":"The incidence, type, and subsequent evolution of 14 variant Ph1 translocations in 180 South African patients with Ph1-positive chronic myeloid leukemia.","volume":"12","author":"Bernstein","year":"1984","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2019111713152121500_B31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/gcc.10056","article-title":"Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.","volume":"34","author":"Loncarevic","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111713152121500_B32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2141.2003.04291.x","article-title":"Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia.","volume":"121","author":"Reid","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111713152121500_B33","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/02841861003660031","article-title":"Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.","volume":"49","author":"Stagno","year":"2010","journal-title":"Acta Oncol"},{"issue":"10","key":"2019111713152121500_B34","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/1097-0142(19801115)46:10<2221::AID-CNCR2820461019>3.0.CO;2-8","article-title":"Chromosomes and causation of human cancer and leukemia: XL, The Ph1 and other translocations in CML.","volume":"46","author":"Sandberg","year":"1980","journal-title":"Cancer"},{"issue":"4","key":"2019111713152121500_B35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000132374","article-title":"Variant Philadelphia translocations in chronic myeloid leukemia.","volume":"44","author":"De Braekeleer","year":"1987","journal-title":"Cytogenet Cell Genet"},{"issue":"2","key":"2019111713152121500_B36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0950-3536(97)80006-6","article-title":"Cytogenetics of chronic myelogenous leukaemia.","volume":"10","author":"O'Brien","year":"1997","journal-title":"Baillieres Clin Haematol"},{"issue":"2","key":"2019111713152121500_B37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"2019111713152121500_B38","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"2019111713152121500_B39","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111713152121500_B40","first-page":"1181","article-title":"A dual colour dual fusion fluorescence in situ hybridization study on the genesis of complex variant translocations in chronic myelogenous leukaemia.","volume":"19","author":"So","year":"2008","journal-title":"Oncol Rep"},{"issue":"2","key":"2019111713152121500_B41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.01.011","article-title":"Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia.","volume":"167","author":"Zagaria","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"16","key":"2019111713152121500_B42","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1200\/JCO.2009.26.7963","article-title":"Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.","volume":"28","author":"Castagnetti","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/25\/6793\/1338475\/zh802511006793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/25\/6793\/1338475\/zh802511006793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T13:15:55Z","timestamp":1573996555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/25\/6793\/24318\/Variant-Philadelphia-translocations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,23]]},"references-count":42,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2011,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-328294","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,23]]}}}